Allena Pharmaceuticals Stock News

Zacks Investment Research upgraded shares of Allena Pharmaceuticals (NASDAQ:ALNA) from a hold rating to a buy rating in a research report report published on Monday morning, Zacks.com reports. Zacks Investment Research currently has $0.75 price target on the stock. According to Zacks, Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing []

Cortexyme (NASDAQ:CRTX) and Allena Pharmaceuticals (NASDAQ:ALNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings. Institutional & Insider Ownership 62.7% of Cortexyme shares are held by institutional investors. Comparatively, 27.1% of []

Golden Minerals Company (AUMN) with the stream of -5.15% also noticed, India Allena Pharmaceuticals, Inc. (ALNA) encountered a rapid change of -7.63% in the last hour of Fridays trading session. The post Silvery Stock: Golden Minerals Company (AMEX:AUMN), Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) appeared first on Stocks Equity .

Allena Pharmaceuticals, Inc. (ALNA) with the stream of -5.30% also noticed, India Senseonics Holdings, Inc. (SENS) encountered a rapid change of -1.55% in the last hour of Mondays trading session. The post Latest Analysts Reports: Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), Senseonics Holdings, Inc. (AMEX:SENS) appeared first on Stocks Equity .

Geode Capital Management LLC raised its position in Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) by 11.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 285,567 shares of the companys stock after purchasing an additional 29,323 shares during the quarter. Geode Capital Management LLCs holdings in []

Zacks Investment Research upgraded shares of Allena Pharmaceuticals (NASDAQ:ALNA) from a hold rating to a buy rating in a research report released on Monday morning, Zacks.com reports. Zacks Investment Research currently has $0.75 target price on the stock. According to Zacks, “Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral […]

The heavy selling pressure might have exhausted for Allena Pharmaceuticals, Inc. (ALNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wa

Allena Pharmaceuticals, Inc. (ALNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revis

Allena Pharmaceuticals (ALNA) has been struggling lately, but the selling pressure may be coming to an end soon.

Allena Pharmaceuticals, Inc. (ALNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revis

The heavy selling pressure might have exhausted for Allena Pharmaceuticals, Inc. (ALNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wa

Allena Pharmaceuticals (ALNA) has been struggling lately, but the selling pressure may be coming to an end soon.

Level Four Financial LLC grew its position in Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) by 100.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,000 shares of the companys stock after acquiring an additional 20,000 shares during the quarter. Level Four Financial []

Zacks Investment Research downgraded shares of Allena Pharmaceuticals (NASDAQ:ALNA) from a buy rating to a hold rating in a research report report published on Friday morning, Zacks.com reports. According to Zacks, Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic []

Zacks Investment Research upgraded shares of Allena Pharmaceuticals (NASDAQ:ALNA) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $1.00 price objective on the stock. According to Zacks, Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and []